Comparative Pharmacology
Head-to-head clinical analysis: DELSYM versus PROVAL 3.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DELSYM versus PROVAL 3.
DELSYM vs PROVAL #3
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dextromethorphan is a non-competitive NMDA receptor antagonist and sigma-1 receptor agonist, which suppresses cough by elevating the threshold for coughing in the medullary cough center.
Proval #3 is a combination of acetaminophen (paracetamol), butalbital, and caffeine. Acetaminophen inhibits cyclooxygenase (COX) enzymes, reducing prostaglandin synthesis in the CNS, raising the pain threshold. Butalbital is a barbiturate that enhances GABA-A receptor activity, producing sedation and anxiolysis. Caffeine is a CNS stimulant that potentiates analgesic effects via adenosine receptor antagonism.
60 mg orally every 12 hours (extended-release suspension).
1-2 tablets orally every 4-6 hours as needed for pain; not to exceed 8 tablets per day.
None Documented
None Documented
Terminal elimination half-life of dextromethorphan is approximately 11 hours (range 9-14 hours) in extensive metabolizers; in poor metabolizers (CYP2D6 deficiency), half-life can exceed 24 hours, leading to accumulation.
4–6 hours in adults with normal hepatic function; prolonged in hepatic impairment (8–12 hours).
Renal excretion of unchanged drug and metabolites, primarily dextrorphan glucuronide; <5% excreted unchanged in urine. Biliary/fecal elimination is negligible.
Primarily hepatic metabolism (CYP450) with <5% excreted unchanged in urine. Biliary/fecal elimination accounts for ~15% as metabolites.
Category C
Category C
Antitussive
Antitussive